ocrelizumab
antiantibody
brentuximab
toxin antitoxin
dorlixizumab
cergutuzumab
anticorrelate
tisotumab
teplizumab
autocentromere
talizumab
immunocharacterize
antipolyvalent
bispecific
tabalumab
hyperimmunoglobulin
antisynthetase
guselkumab
lorvotuzumab
immunotoxicity
heterophile
-ab
agonistic monoclonal antibody
caplacizumab
sifalimumab
antiustekinumab
bivatuzumab
-o-
agglutinin
ixekizumab
-kin-
polytypic
presentation
microlymphocytotoxicity
-ner-
polyantibody
immunosphere
abzyme
polyvalent
elotuzumab
tucotuzumab
sonepcizumab
cytoimmunity
soravtansine
heteroclitic
clenoliximab
antiimmunoglobulin
ibritumomab
immunomolecule